BioPrintIA
ReadyCell collaborates in the BioPrintIA project as a specialized partner in the biotechnology sector. BioPrintIA is a subsidised R&D project that develops a next-generation medical device based on artificial intelligence,…
ReadyCell collaborates in the BioPrintIA project as a specialized partner in the biotechnology sector. BioPrintIA is a subsidised R&D project that develops a next-generation medical device based on artificial intelligence,…
ReadyCell actively interacts with the Drug Discovery community, introducing cell-based in vitro systems and easing novel compounds’ preclinical development.
Culturing Caco-2 cells in Transwell plates is considered the reference in vitro technique to evaluate intestinal permeability in novel orally administered compounds, according to leading regulatory agencies (FDA, EMA and…
Cellular models are the most used in vitro technique for novel drug studies during preclinical drug discovery phases. Cell lines provide a pure population of cells, are easy to use,…
The liver and the kidneys have clearly defined various physiologic functions, their role as excretory organs for drugs and chemicals and their polar metabolites are well described. These organs have…